# ADARx (ADRX) — News

ADRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/adrx/news

## Recent headlines

- [HBM Healthcare Investments posts solid half-year result – expected profit of CHF 177 million](https://www.ainvest.com/news/hbm-healthcare-investments-posts-solid-year-result-expected-profit-chf-177-million-2610) — AInvest Wire, Oct 1, 2026
  HBM Healthcare Investments AG has reported a strong half-year performance, with an expected profit of CHF 177 million for the period. This result reflects continued growth and successful investment strategies across its portfolio companies. The firm has recently made significant investments in…
- [Adarx Pharmaceuticals opens at $22.10, IPO at $17](https://www.ainvest.com/news/adarx-pharmaceuticals-opens-22-10-ipo-17-2609) — AInvest Wire, Sep 25, 2026
  ADARx Pharmaceuticals (ADRX) shares opened at $22.10 on Friday, September 25, 2026, on the NASDAQ, surpassing the initial public offering (IPO) price of $17.00 per share. The company raised $446.25 million by upsizing its IPO to 26.25 million shares, up from the 21.88 million shares outlined in the…
- [Adarx Pharmaceuticals indicated to open at $24, IPO price $17](https://www.ainvest.com/news/adarx-pharmaceuticals-open-24-ipo-price-17-2609) — AInvest Wire, Sep 25, 2026
  Adarx Pharmaceuticals is set to begin trading on the public market following its initial public offering (IPO), with shares expected to open at $24, above the IPO price of $17 per share. The pricing reflects strong investor demand for the company’s innovative drug development pipeline and its focus…
- [Adarx Pharma said to allocate 55% of IPO shares to 10 investors](https://www.ainvest.com/news/adarx-pharma-allocate-55-ipo-shares-10-investors-2609) — AInvest Wire, Sep 25, 2026
  ADARx Pharmaceuticals, a developer of RNA-based therapeutics, is reportedly allocating 55% of its initial public offering (IPO) shares to a select group of 10 institutional investors, according to recent reports. This allocation strategy is part of the company’s broader IPO plan, which aims to…
- [Adarx Pharmaceuticals indicated to open at $28, IPO price $17](https://www.ainvest.com/news/adarx-pharmaceuticals-open-28-ipo-price-17-2609) — AInvest Wire, Sep 25, 2026
  ADARx Pharmaceuticals (ADRX), which priced its initial public offering at $17 per share on September 23, indicated an opening price of $28 on its first day of trading on the Nasdaq on September 24. The offering raised approximately $350 million at midpoint, with 21.9 million primary shares offered…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).